Indaptus Therapeutics, Inc. (INDP) Stock Score, Valuation & Financial Research

Indaptus Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for INDP

Indaptus Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.30. These figures are a research snapshot, not a buy or sell recommendation.

What Indaptus Therapeutics, Inc. does

Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Indaptus Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, non-pathogenic, attenuated bacterial-based immunotherapies. The company operates as a research and development entity and does not currently generate revenue from product sales, relying instead on capital raises and financing activities to fund its clinical trials and operations.

Products and services

  • The company's primary product candidate is Decoy20, an attenuated bacterial-based immunotherapy designed to activate both innate and adaptive immune responses for the treatment of solid tumors and hematologic malignancies.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials. Source

Business strengths to evaluate

  • Proprietary bacterial-based immunotherapy platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Need for additional capital to fund operations Source
  • Clinical trial development and regulatory approval risks Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

INDP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.30
Market capitalization:
260.46M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -15.42M
Free cash flow:
USD -14.82M
Cash:
USD 7.55M
Total debt:
USD 0.00
EPS:
USD -6.97

What stands out

  • Free cash flow is USD -14.82M, negative for the stored period.
  • The balance sheet shows USD 7.55M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7.55M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for INDP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can INDP fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is INDP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for INDP to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of INDP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research INDP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.